StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)

Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –

Arcutis Biotherapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Arcutis Biotherapeutics's total debt was $108.90M at Jun 30, 2026. For fiscal 2025 it was $108.96M, up 1.6% from the year before. The highest annual figure on record is $201.80M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$108.96M+1.6%
FY2024Dec 31, 2024$107.20M-46.9%
FY2023Dec 31, 2023$201.80M+2.0%
FY2022Dec 31, 2022$197.77M+173.4%
FY2021Dec 31, 2021$72.35M–
FY2020Dec 31, 2020$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$108.90M+0.8%
Q1 FY2026Mar 31, 2026$109.42M+1.7%
Q4 FY2025Dec 31, 2025$108.96M+1.6%
Q3 FY2025Sep 30, 2025$108.50M-47.0%
Q2 FY2025Jun 30, 2025$108.05M-47.0%
Q1 FY2025Mar 31, 2025$107.62M-46.9%
Q4 FY2024Dec 31, 2024$107.20M-46.9%
Q3 FY2024Sep 30, 2024$204.61M+1.9%
Q2 FY2024Jun 30, 2024$203.81M+2.0%
Q1 FY2024Mar 31, 2024$202.80M+2.0%
Q4 FY2023Dec 31, 2023$201.80M+2.0%
Q3 FY2023Sep 30, 2023$200.78M+2.0%
Q2 FY2023Jun 30, 2023$199.77M+173.1%
Q1 FY2023Mar 31, 2023$198.76M+173.2%
Q4 FY2022Dec 31, 2022$197.77M+173.4%
Q3 FY2022Sep 30, 2022$196.75M–
Q2 FY2022Jun 30, 2022$73.14M–
Q1 FY2022Mar 31, 2022$72.74M–
Q4 FY2021Dec 31, 2021$72.35M–
Q4 FY2020Dec 31, 2020$0–

More Arcutis Biotherapeutics figures

See a number that looks wrong?